KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:KYMR

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/30	21:00	GlobeNewswire Inc.	Kymera Therapeutics to Participate in Upcoming February Investor Conferences	NASDAQ:KYMR	Kymera Therapeutics Inc
2025/01/15	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KYMR	Kymera Therapeutics Inc
2025/01/14	21:00	GlobeNewswire Inc.	Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs	NASDAQ:KYMR	Kymera Therapeutics Inc
2025/01/13	21:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2025/01/13	21:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2025/01/07	21:00	GlobeNewswire Inc.	Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/11/26	21:00	GlobeNewswire Inc.	Kymera Therapeutics to Participate in Upcoming December Investor Conferences	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/11/05	21:00	GlobeNewswire Inc.	Kymera Therapeutics to Participate in Upcoming November Investor Conferences	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/31	21:13	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/31	20:45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/31	20:40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/31	20:30	GlobeNewswire Inc.	Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/24	20:00	GlobeNewswire Inc.	Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/23	20:15	GlobeNewswire Inc.	Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/23	20:00	GlobeNewswire Inc.	Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/10/09	20:00	GlobeNewswire Inc.	Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/09/25	20:00	GlobeNewswire Inc.	Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/28	20:00	GlobeNewswire Inc.	Kymera Therapeutics to Participate in Upcoming September Investor Conferences	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/22	00:15	GlobeNewswire Inc.	Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/21	06:24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/21	05:31	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/20	11:45	GlobeNewswire Inc.	Kymera Therapeutics Announces Pricing of $225 Million Public Offering	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/20	05:01	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/20	05:01	GlobeNewswire Inc.	Kymera Therapeutics Announces Proposed Public Offering	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/07	20:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/07	20:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/08/07	20:00	GlobeNewswire Inc.	Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/07/31	20:00	GlobeNewswire Inc.	Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/07/17	07:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/07/17	05:28	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:KYMR	Kymera Therapeutics Inc